A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation.
Saved in:
| Title: | A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation. |
|---|---|
| Authors: | Giorgino F; Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy. Electronic address: francesco.giorgino@uniba.it., Taybani Z; 1st Department of Endocrinology, Békés County Central Hospital, Dr Réthy Pál Member Hospital, Békécsaba, Hungary., Cheng A; Trillium Health Partners and Unity Health Toronto, Toronto, ON, Canada., Tebaibia A; Faculty of Medicine, University of Algiers 1, Algiers, Algeria., Anaforoglu İ; Acıbadem University School of Medicine, Istanbul, Türkiye., Lauand F; Sanofi, Paris, France., Servera S; Sanofi, NJ, USA., Li X; Sanofi, NJ, USA., Fonseca V; Tulane University Medical Center, New Orleans, LA, USA. |
| Source: | Diabetes research and clinical practice [Diabetes Res Clin Pract] 2025 Nov; Vol. 229, pp. 112945. Date of Electronic Publication: 2025 Oct 13. |
| Publication Type: | Journal Article; Observational Study |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8227 (Electronic) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1872-8227 |
|---|---|
| DOI: | 10.1016/j.diabres.2025.112945 |
